Cellectar Biosciences Price To Book vs. Return On Asset
| CLRB Stock | USD 0.26 0.05 16.13% |
For Cellectar Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cellectar Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cellectar Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cellectar Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cellectar Biosciences over time as well as its relative position and ranking within its peers.
Cellectar |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cellectar Biosciences Return On Asset vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cellectar Biosciences's current stock value. Our valuation model uses many indicators to compare Cellectar Biosciences value to that of its competitors to determine the firm's financial worth. Cellectar Biosciences is rated fifth in price to book category among its peers. It is rated below average in return on asset category among its peers . The current year's Return On Assets is expected to grow to -2.99. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cellectar Biosciences' earnings, one of the primary drivers of an investment's value.Cellectar Return On Asset vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Cellectar Biosciences |
| = | 6.93 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Cellectar Biosciences |
| = | -1.66 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Cellectar Return On Asset Comparison
Cellectar Biosciences is currently under evaluation in return on asset category among its peers.
Cellectar Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cellectar Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cellectar Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Cellectar Biosciences' change in net profit over the period of time. It can combine multiple indicators of Cellectar Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.6 M | -1.7 M | |
| Operating Income | -39 M | -37 M | |
| Income Before Tax | -38 M | -36.1 M | |
| Total Other Income Expense Net | 917.1 K | 963 K | |
| Net Loss | -38 M | -36.1 M | |
| Income Tax Expense | 60 K | 63 K | |
| Net Loss | -37.7 M | -35.9 M | |
| Non Operating Income Net Other | 166.8 K | 158.4 K | |
| Net Loss | -25.7 M | -24.5 M | |
| Interest Income | 395.4 K | 649.7 K | |
| Net Interest Income | 395.4 K | 415.1 K | |
| Change To Netincome | 1.8 M | 1.9 M | |
| Net Loss | (3.11) | (3.26) | |
| Income Quality | 0.85 | 0.53 | |
| Net Income Per E B T | 1.00 | 0.66 |
Cellectar Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cellectar Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cellectar Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cellectar Biosciences' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Cellectar Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
| All Next | Launch Module |
Use Investing Themes to Complement your Cellectar Biosciences position
In addition to having Cellectar Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Market Neutral Funds Thematic Idea Now
Market Neutral Funds
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
To fully project Cellectar Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cellectar Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cellectar Biosciences' income statement, its balance sheet, and the statement of cash flows.